Subcortical band heterotopia (SBH) is a developmental brain disorder whose symptoms vary from normal intelligence quotient to severe mental retardation and intractable epilepsy 1 . The condition arises when cortical neurons fail to migrate to the correct location, resulting in an aberrant 'band-like' accumulation of neurons within the neocortical white matter (called heterotopia-literally 'other place').
Current treatments for patients with epilepsy SBH are exclusively symptomatic, aimed at reducing seizure frequency and severity. Unfortunately, SBH seizures are mostly refractory to medication, and surgical resections of epileptic foci are ineffective in these particular cases 2 . When prenatal diagnostics show SBH, expectant parents facing the potential-and unpredictable-severity of the condition and the lack of effective treatments often choose to terminate the pregnancy.
Findings in this issue of Nature Medicine by Manent et al. 3 could lead to other options. The authors introduce a postnatal molecular intervention that partially rescues a rat model of SBH, both morphologically and functionally 3 . This study has broader implications for hard-to-treat neuron migration disorders and for epilepsy.
Proper neocortical function requires appropriate neuronal positioning. During midembryonic development, cortical pyramidal neurons are generated adjacent to the lateral ventricle. Then, they migrate radially toward the surface of the brain to reach the cortical plate and subsequently establish synaptic connections. In the past 50 years, several conditions showing neuron migration disorders (NMDs), frequently associated with the most severe forms of epilepsy, have been described, and many of the crucial factors regulating this developmental step have been identified 4 . However, our capacity to manipulate migration in vivo to create new treatment options has not been realized. It has generally been accepted that once a child is born with SBH or a related condition it is too late to consider curative treatments, as brain morphology is already set in place.
Most individuals with SBH have mutations in the gene encoding doublecortin (DCX). DCX has a key role in neuronal migration by binding and stabilizing microtubules as cells migrate toward the brain surface. Mutations of DCX in humans lead predominantly to SBH (aka 'double cortex' syndrome) in females and to the more severe lissencephaly (aka 'smooth brain' syndrome) in males 5 .
LoTurco's laboratory previously showed that acute knockdown of Dcx, by way of in utero electroporation of Dcx short hairpin RNA (shRNA), induces marked cortical migration defects in rat and mouse 6 . Moreover, in rat only, Dcx knockdown induces the formation of a massive band of abnormally positioned neurons lying between the ventricular walls and the cortical plate, thus constituting a powerful rodent model to test potential SBH therapies 7 .
A few other animal models of SBH are currently studied, such as the spontaneous mutant tish rat model 8 , the HeCo mouse model 9 or the antimitotic methylazoxy methanol prenatal injection model 8 . In vitro rescue experiments have been conducted showing that neurons of methylazoxy methanol-treated brain ferret cortical slices were able to migrate more effectively into adjacent co-cultured normal cortical plate 10 . However, no in vivo rescue of NMDs has been reported, leaving open the question of whether gene therapy or other such options might someday help treat these disorders.
Manent et al. 3 tested whether a delayed reexpression of Dcx could restimulate the migration of stalled neurons to result in regression of the SBH. This delay is a key feature that mimics the incompressible time period between the phenotype completion, the diagnosis and the treatment. The delay was enabled by electroporating the Dcx knockdown shRNA vector with n e w s a n d v i e w s a drug-inducible Dcx expression vector system into cortical neurons. Unexpectedly, the postnatal reexpression of Dcx was able to stimulate the migration of neurons already settled in the heterotopic band, leading to a significant reduction of the size of SBH. Additionally, rescued neurons migrated to their correct laminar positions and adopted a normal morphology (Fig. 1) . Moreover, the treatment seemed to lessen the symptoms of disease, decreasing the susceptibility to pentylenetetrazol-induced seizures in the rat model used. Such a successful rescue only occurred in rat in a short postnatal time window between the day of birth and the fifth postnatal day, which, if applicable to humans, would roughly correspond to late prenatal to early postnatal ages. This crucial feature of the Dcx-induced SBH rescue makes potential molecular intervention possible in people. Indeed, in utero intraventricular cerebral injections should be performed safely in the future, as advances in fetal surgery continue and even more safely after birth.
Although it is exciting to consider potential treatments for these seemingly incurable neurodevelopmental disorders, this particular experimental intervention is clearly not applicable to humans, as the authors point out 3 . In this study, both the problem (the Dcx shRNA) and the solution (the inducible Dcx-encoding vector) are introduced simultaneously in a population of neurons. Thus, only those cells in which Dcx is knocked down are later subject to forced reexpression of Dcx. The electroporation procedure could be replaced by a viral injection in humans with a DCX mutation, but the precise targeting of the heterotopic neurons would remain problematic. However, precise targeting of heterotopic neurons may not be necessary. Dcx overexpression in embryonic cortical neurons causes cells to adopt highly bipolar morphology 11 , but consequences on more mature neurons remain to be tested and would need to be balanced with any potential clinical improvement in individuals with SBH.
Finally, if Dcx-delayed reexpression can reactivate migration, could other actors of neuronal migration function similarly? Conversely, could Dcx reexpression rescue migration defects caused by other or still unidentified gene mutations 12 ? In other words, is the recovery observed by Manent et al. 3 specific to compensation of Dcx deficiency, or can Dcx reexpression generally reactivate or promote migration? For instance, Dcx can compensate for in vitro migration defects induced by deficiency of PAFAH1B (platelet-activating factor acethylhydrolase 1B subunit, encoding LIS1), another migration-stimulating and SBHcausing gene 13 . The answers to questions such as these could lead to new ways to improve outcome for a host of NMDs as well as other neurodevelopmental disorders.
Mesenchymal stem cells (MSCs), enigmatic multipotent cells found in many tissues of the body, were first described in 1968 (ref. 1). These precursor cells looked like fibroblasts, adhered to plastic and could differentiate into stromal tissues such as bone. This cell type is now receiving enormous attention in numerous biomedical fields, including regenerative medicine, tissue protection, graft enhancement and immunomodulation.
A study of mice in this issue of Nature Medicine 2 suggests that these cells might also be useful as a therapy for sepsis, a form of serious blood infection that kills 35,000 each year in the United States.
Since the identification of MSCs, the nomenclature and definition of the heterogenous population of cells has been inconsistent. This cell type has not been shown to be a true 'stem' cell in that on division, one daughter cell is able to replenish a whole tissue compartment while the other remains fully stem like. However, most researchers agree on a few criteria for calling a cell an MSC: the ability to form colonies in culture with typical stromal surface markers and absence of hematopoietic markers, as well as the potential for differentiation into at least three stromal tissue types 3 . MSCs may be obtained from various tissues, including bone marrow (the original source), adipose tissue and placenta. Unlike hematopoietic stem cells, MSCs cannot be mobilized from the bone marrow into peripheral blood, nor does ex vivo expansion of MSCs result in terminal tissue differentiation. In addition, MSCs enjoy some degree of immune privilege in that allogeneic MSCs may be infused intravenously into the host without the need for immunosuppression or chemotherapeutic conditioning.
Acute toxicity in humans has not been seen, although the long-term safety in terms of tumor surveillance is still unclear, since several animal models have shown enhanced metastasis after MSC infusion 4 . Many animal models of immunosuppression and tissue protection have been published, and in vitro studies have shown both contact factors and soluble molecules as being responsible for the immunosuppression 5 , although some of these studies have been challenged.
MSCs operate through a variety of effector mechanisms on key cells of the innate and adaptive immune systems, mostly through manipulating the cell cycle or inducing maturation arrest without apoptosis 6 . Recently, human
